ASAKE BIOTECHNOLOGY, LLC

Biotech · Private

Small-molecule therapeutic (MSB-3) for type 1 diabetes that protects beta cells from cytokine-induced death and enhances insulin production

Grants
$2.3M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A dual-acting small molecule for the treatment of type 1 diabetes$299,974
Federal grantDepartment of Health and Human Services · Phase II · A dual-acting small molecule for the treatment of type 1 diabetes$609,183
Federal grantDepartment of Health and Human Services · Phase II · A dual-acting small molecule for the treatment of type 1 diabetes$740,897
Federal grantDepartment of Health and Human Services · Phase II · A dual-acting small molecule for the treatment of type 1 diabetes$625,501
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1747Airway Therapeutics, LLC—$54M
1748Quoin Pharmaceuticals, Ltd.—$164M
1749Tempo Therapeutics Inc—$34M
1750ASAKE BIOTECHNOLOGY, LLC——
1751ANTHROBIO, INC.——
1752Torque Medical Holdings, LLC—$4.7M
1753Navitor Pharmaceuticals—$65M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.